EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B

Niamh O'Connell, Paul van der Valk, Sandra Le Quellec, Esteban Gomez, Paul E Monahan, Shelley E Crary, Michiel Coppens, Richard Lemons, Giancarlo Castaman, Robert Klamroth, Emily Symington, Doris V Quon und 1 weitere

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2024.08.027 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Niamh O'Connell und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Coagulation Centre, St. James's Hospital, Dublin, Ireland; School of Medicine, Trinity College, Dublin, Ireland. Electronic address: noconne…. Hauptthemen laut MEDLINE: Factor IX, Genetic Therapy, Hemophilia B, Postoperative Hemorrhage. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Behring LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Little information regarding the management of invasive procedures in people with hemophilia B (HB) after undergoing gene therapy is available. Here, we report the management of invasive procedures in people with severe or moderately severe HB who had previously been treated with etranacogene dezaparvovec in the phase 2b and phase 3 Health Outcomes with Padua Gene; Evaluation in Hemophilia B clinical trials (NCT03489291 and NCT03569891). OBJECTIVES: The objective of this study was to describe the use of exogenous FIX, endogenous FIX activity prior to invasive procedures, and peri- and postoperative bleeds in participants who underwent invasive procedures after receiving etranacogene dezaparvovec gene therapy. METHODS: This retrospective analysis included invasive procedures performed within 3 and 2 years following a single infusion of 2 × 1013 gc/kg of etranacogene dezaparvovec in participants in the phase 2b and Health Outcomes with Padua Gene; Evaluation in Hemophilia B trials, respectively. Data for factor (F)IX dosing, duration of postoperative FIX use, FIX activity prior to invasive procedures, and postoperative bleeds were collected and analyzed. RESULTS: The analysis included 64 procedures in 29 participants: 9 major surgeries, 24 minor surgeries, 11 endoscopies, 3 endoscopies with biopsy/polypectomy, and 17 dental procedures. Uncontaminated endogenous FIX activity corresponded to mild hemophilia or normal levels prior to 98% of all procedures, with a median endogenous FIX activity of 43.8 IU/dL (range, 3.1-113 IU/dL). All major surgeries were managed with exogenous FIX, 67% with ≤4 days of FIX infusion. Most minor surgeries (88%), endoscopies (82%), and dental procedures (94%) were managed with no or a single FIX infusion. Postoperative bleeds occurred after 1 minor surgery and 4 dental procedures. There were no symptomatic thrombotic events or FIX inhibitor developments. CONCLUSION: Etranacogene dezaparvovec has the potential to facilitate perioperative management in people with HB by reducing the need for perioperative exogenous FIX and its associated risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXGenetic TherapyHemophilia BPostoperative HemorrhageAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultRetrospective StudiesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

factor IX-Paduagene therapyhemophilia Binvasive procedure

Substanzen

Factor IX

Autor:innen und Institutionen

  • National Coagulation Centre, St. James's Hospital, Dublin, Ireland; School of Medicine, Trinity College, Dublin, Ireland. Electronic address: noconnell@stjames.ie.
  • Van Creveldkliniek, Department of Benign Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • CSL Behring, King of Prussia, Pennsylvania, USA.
  • The Center for Inherited Blood Disorders, Orange, California, USA.
  • Department of Pediatrics, Hematology and Oncology, Arkansas Children's Hospital, Little Rock, Arkansas, USA.
  • Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherla…

Förderung

  • CSL Behring LLC

Zitieren

APA

O'Connell, N., van der Valk, P., Le Quellec, S., Gomez, E., Monahan, P. E., Crary, S. E., Coppens, M., Lemons, R., Castaman, G., Klamroth, R., Symington, E., Quon, D. V., & Kampmann, P. (2025). Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.08.027

Vancouver

O'Connell N, van der Valk P, Le Quellec S, Gomez E, Monahan PE, Crary SE, et al. Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.08.027

BibTeX
@article{OConnell2025,
  author = {O'Connell, Niamh and van der Valk, Paul and Le Quellec, Sandra and Gomez, Esteban and Monahan, Paul E and Crary, Shelley E and Coppens, Michiel and Lemons, Richard and Castaman, Giancarlo and Klamroth, Robert and Symington, Emily and Quon, Doris V and Kampmann, Peter},
  title = {Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2024.08.027}
}
Kostenlos starten →